Aleve PM Enters Nighttime Pain-Relief Market After 160-Count Label Approved
This article was originally published in The Tan Sheet
Executive Summary
Bayer HealthCare business on Sept. 15 announced the product with 220mg naproxen sodium and 25mg diphenhydramine HCL is available at U.S. retailers. Its NDA was approved in January, but Bayer waited for FDA’s OK on 160-count labeling before launching the product.
You may also be interested in...
Apotex' Aleve PM Rival Could Have 180-Day Exclusivity As A CGT
US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), the FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.
Latest Aleve PM Copy Could Have 180-Day Exclusivity From More Competition
US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.